Around the world, 2.5 billion people need assistive products and services. Yet nearly one billion of them are denied access, particularly in low- and middle-income countries, where access can be as low as 3 percent of the need for these life-changing products. For...
As part of a growing portfolio of biomedical HIV prevention options, long-acting injectable cabotegravir (CAB-LA) was approved by the US FDA in December 2021. Evidence from two clinical trials, HPTN 083 and HPTN 084, which enrolled nearly 8,000 participants across 13...
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI.
A critical second-line HIV treatment called darunavir/ritonavir (DRV/r) is rolling out across Nigeria and Zambia – some of the earliest adopters of many countries that can now access an affordable supply of these medicines following a pricing agreement secured by CHAI and Unitaid last year.
With CHAI support, Nasarawa State in Nigeria has rolled out integrated hepatitis C and HIV testing.
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI.
Global AIDS fight 'in danger' but there is still time to get back on track, participants hear at AIDS 2022 conference. A few short weeks ago, CHAI marked the start of our 20th anniversary. We remembered the 2002 AIDS conference in Barcelona, which helped launch our...
As Nigeria prepares to roll out the HIV/syphilis dual test, health workers share why it is so critical for pregnant women.
CHAI spoke with HIV advocate and Director of the African Community Advisory Board (AfroCAB) Treatment Access Partnership Kenly Sikwese about why self-testing is such an important option to make available for people who want to check their HIV status.
CHAI’s recently released Hepatitis C Market Memo is an update to the previous editions of Hepatitis market reports. It provides critical insights into the market and helps the public and private sectors develop better strategies to provide products and services to...
